TRVI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Trevi Therapeutics Inc (TRVI) is not a strong buy for a beginner investor with a long-term focus at this moment. Despite some positive catalysts such as strong market confidence in its public offering and bullish technical indicators, the stock's pre-market price drop of -8.53% and weak financial performance suggest caution. The lack of strong proprietary trading signals and overbought RSI also indicate that waiting for a better entry point may be prudent.
The stock shows bullish technical indicators with a positively expanding MACD histogram (0.258), bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a pivot level at 13.125. However, the RSI of 88.079 indicates the stock is overbought, and the pre-market price drop of -8.53% suggests potential short-term weakness.
Strong market demand and investor confidence in the $150 million public offering.
Bullish technical indicators such as MACD and moving averages.
Analysts maintain Buy and Overweight ratings with price targets significantly above the current price.
Pre-market price drop of -8.53%.
Weak financial performance in Q4 2025, with net income and EPS declining significantly YoY.
Overbought RSI indicating potential for a pullback.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income drop of -27.15% YoY to -$8.316 million, and a significant EPS decline of -45.45% YoY to -0.06.
Analysts maintain positive ratings with a Buy and Overweight stance. Price targets were slightly lowered (from $25 to $24 and $19 to $18) but still indicate significant upside potential from the current price.
